Anti-fXI antibodies and methods of use
AssigneesOregon Health & Science University, Vanderbilt University
InventorsAndras Gruber, Erik I. Tucker, David Gailani
Life of this patent
Estimating the term…
Abstract
Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.
Claims12
An isolated nucleic acid molecule encoding a monoclonal antibody, or an antigen-binding fragment thereof, specific for coagulation factor XI (fXI), wherein:
- the variable light chain (VL) of the antibody comprises amino acids 24-34, 50-63 and 91-98 of SEQ ID NO:
- 1;
- and
- the variable heavy chain (VH) of the antibody comprises amino acids 31-35, 50-68 and 98-105 of SEQ ID NO:
- 3.
An isolated nucleic acid molecule encoding an immunoconjugate comprising a monoclonal antibody, or an antigen-binding fragment thereof, specific for fXI and a fusion partner, wherein:
- the variable light chain (VL) of the antibody comprises amino acids 24-34, 50-63 and 91-98 of SEQ ID NO:
- 1;
- and
- the variable heavy chain (VH) of the antibody comprises amino acids 31-35, 50-68 and 98-105 of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.